Security Snapshot

Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL) Institutional Ownership

CUSIP: 95075A107

13F Institutional Holders and Ownership History from Q2 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

28

Shares (Excl. Options)

8.37MFull value: 8,368,966 · shares · 30 Sep 2026

Price

$0.92

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-1,643,520
Value change
+$203,121
Number of holders
28
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
48,566,310
SEC-reported price per share
$0.98
Insider filing price
$0.98
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • HOWL - Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 95075A107.
  • 28 institutions reported positions in Q3 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 45 to 28 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $3.91MFull value: $3,912,160 · USD · 30 Jun 2026
    to
    $7.72MFull value: $7,720,130 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 28 institutions filings for Q3 2026.

Open SEC evidence

Security key

95075A107

13F reference period

Q3 2026

13F holders

28

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
HOWL
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BALYASNY ASSET MANAGEMENT L.P. 6.3% $2,979,446 3,040,251 BALYASNY ASSET MANAGEMENT L.P. 30 Sep 2026
MOLL PETER 5.2% $2,384,910 2,537,138 MOLL PETER 18 Sep 2026
RA CAPITAL MANAGEMENT, L.P. 4.1% -32% $734,650 -$344,174 1,985,541 -32% RA Capital Management, L.P. 30 Jun 2026
MPM BioVentures 2014, L.P. 3.8% -32% $1,680,514 -$719,307 1,826,646 -30% ANSBERT GADICKE 08 May 2026
Longwood Fund III, L.P. 3.5% $955,937 1,677,082 Longwood Fund III GP, LLC 31 Dec 2025
PFM Health Sciences, LP 0.9% -80% $437,210 -$2,729,747 401,110 -86% PFM Health Sciences, LP 30 Jun 2025
As of 30 Sep 2026, 28 institutional investors reported holding
8.37MFull value: 8,368,966 · shares · 30 Sep 2026
shares of Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL). This represents 17% of the company’s total
48.57MFull value: 48,566,310 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 24 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
9.6%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD CAPITAL MANAGEMENT LLC 2.5% 1,217,976 0% $1,122,974
Lynx1 Capital Management LP 1.4% 657,786 0.09% $606,676
SPHERA FUNDS MANAGEMENT LTD. 1.3% 626,810 0.09% $578,107
RENAISSANCE TECHNOLOGIES LLC 1.1% 550,935 0% $508,127
GEODE CAPITAL MANAGEMENT, LLC 0.84% 407,145 0% $375,601
VANGUARD FIDUCIARY TRUST CO 0.55% 266,666 0% $245,866
XTX Topco Ltd 0.43% 209,611 0% $193,324
BANK OF AMERICA CORP /DE/ 0.35% 171,631 0% $158,243
STATE STREET CORP 0.25% 119,168 0% $109,909
Alyeska Investment Group, L.P. 0.18% 86,554 0% $79,829
Vontobel Holding Ltd. 0.12% 60,000 0% $55,338
StoneX Group Inc. 0.11% 54,856 0% $51,099
Vilga Financial Planning LLC 0.11% 53,423 0.03% $49,272
Vanguard Global Advisers, LLC 0.06% 30,550 0% $28,167
GOLDMAN SACHS GROUP INC 0.06% 28,533 0% $26,316
LPL Financial LLC 0.05% 23,069 0% $21,277
TWO SIGMA SECURITIES, LLC 0.04% 20,578 0% $18,979
CERTUITY, LLC 0.03% 15,000 0% $13,835
HBK Sorce Advisory LLC 0.03% 13,737 0% $14,012
Marest Capital, LLC 0.02% 10,870 0.01% $10,025
Financial Perspectives, Inc 0.01% 6,750 0% $6,226
SBI Securities Co., Ltd. 0% 130 0% $120
Optiver Holding B.V. 0% 22 0% $20
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.08% 41,100 0% $37,812

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Headline period
Q3 2026
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 8,368,966 $7,720,130 +$203,121 $0.92 28
2026 Q2 10,864,466 $3,912,160 -$1,467,220 $0.36 45
2026 Q1 13,999,904 $11,653,844 -$532,173 $0.83 47
2025 Q4 14,735,208 $9,335,513 -$2,241,745 $0.63 49
2025 Q3 21,108,242 $41,572,612 -$2,103,204 $1.97 62
2025 Q2 22,335,758 $24,343,246 -$5,335,449 $1.09 65
2025 Q1 27,445,533 $26,679,025 -$940,155 $0.97 70
2024 Q4 28,177,146 $41,701,476 -$7,785,512 $1.48 71
2024 Q3 32,205,548 $68,274,106 -$1,018,677 $2.12 68
2024 Q2 32,469,409 $79,220,415 -$5,272,473 $2.44 70
2024 Q1 32,251,087 $208,968,732 +$29,830,206 $6.48 59
2023 Q4 27,669,999 $106,805,060 +$14,923,168 $3.86 41
2023 Q3 23,882,934 $51,107,776 -$364,729 $2.14 34
2023 Q2 24,045,139 $73,334,928 +$110,396 $3.05 36
2023 Q1 24,035,818 $62,491,910 +$8,454,617 $2.60 37
2022 Q4 20,890,957 $42,845,289 -$4,124,677 $2.05 37
2022 Q3 20,956,559 $94,490,128 +$8,517,407 $4.51 39
2022 Q2 19,071,418 $78,002,023 +$194,911 $4.09 39
2022 Q1 18,982,797 $83,522,100 -$5,015,169 $4.40 47
2021 Q4 19,103,784 $227,525,761 -$818,751 $11.91 50
2021 Q3 18,418,726 $316,117,290 -$12,884,754 $17.16 41
2021 Q2 19,169,179 $334,041,360 +$334,041,360 $17.44 44
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .